These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 7536025)

  • 1. High-dose carboplatin, thiotepa and cyclophosphamide (CTC) with peripheral blood stem cell support in the adjuvant therapy of high-risk breast cancer: a practical approach.
    van der Wall E; Nooijen WJ; Baars JW; Holtkamp MJ; Schorangel JH; Richel DJ; Rutgers EJ; Slaper-Cortenbach IC; van der Schoot CE; Rodenhuis S
    Br J Cancer; 1995 Apr; 71(4):857-62. PubMed ID: 7536025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study.
    Bergh J; Wiklund T; Erikstein B; Lidbrink E; Lindman H; Malmström P; Kellokumpu-Lehtinen P; Bengtsson NO; Söderlund G; Anker G; Wist E; Ottosson S; Salminen E; Ljungman P; Holte H; Nilsson J; Blomqvist C; Wilking N
    Lancet; 2000 Oct; 356(9239):1384-91. PubMed ID: 11052580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancer.
    Schrama JG; Baars JW; Holtkamp MJ; Schornagel JH; Beijnen JH; Rodenhuis S
    Bone Marrow Transplant; 2001 Jul; 28(2):173-80. PubMed ID: 11509935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive care.
    Holland HK; Dix SP; Geller RB; Devine SM; Heffner LT; Connaghan DG; Hillyer CD; Hughes LL; Miller RL; Moore MR; Winton EF; Wingard JR
    J Clin Oncol; 1996 Apr; 14(4):1156-64. PubMed ID: 8648370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients.
    Shapiro CL; Ayash L; Webb IJ; Gelman R; Keating J; Williams L; Demetri G; Clark P; Elias A; Duggan D; Hayes D; Hurd D; Henderson IC
    J Clin Oncol; 1997 Feb; 15(2):674-83. PubMed ID: 9053493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease.
    de Graaf H; Mulder NH; Willemse PH; van der Graaf WT; Sleijfer DT; Zijlstra JG; Elias M; Sibinga CT; Vellenga E; de Vries EG
    Anticancer Res; 1995; 15(6B):2851-6. PubMed ID: 8669878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [High-dosage chemotherapy and the autologous transplantation of peripheral hematopoietic progenitor cells in breast cancer: the initial results, analysis of toxicity and the necessary support means].
    Sola Rocabert C; Mesía R; Mendoza L; Tabernero JM; Amill B; Maroto P; Bellet M; Ojeda B; Alonso MC; Verger G
    Med Clin (Barc); 1995 Oct; 105(11):407-11. PubMed ID: 7475451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Harvest quality and factors affecting collection and engraftment of CD34+ cells in patients with breast cancer scheduled for high-dose chemotherapy and peripheral blood progenitor cell support.
    Papadopoulos KP; Ayello J; Tugulea S; Heitjan DF; Williams C; Reiss RF; Vahdat LT; Suciu-Foca N; Antman KH; Hesdorffer CS
    J Hematother; 1997 Feb; 6(1):61-8. PubMed ID: 9112219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer.
    Elias AD; Ayash L; Anderson KC; Hunt M; Wheeler C; Schwartz G; Tepler I; Mazanet R; Lynch C; Pap S
    Blood; 1992 Jun; 79(11):3036-44. PubMed ID: 1350229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The toxicity of radiotherapy following high-dose chemotherapy with peripheral blood stem cell support in high-risk breast cancer: a preliminary analysis.
    van der Wall E; Schaake-Koning CC; van Zandwijk N; Baars JW; Schornagel JH; Richel DJ; Rutgers EJ; Borger JH; Beijnen JH; Rodenhuis S
    Eur J Cancer; 1996 Aug; 32A(9):1490-7. PubMed ID: 8911107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of life in women with breast cancer during the first year after random assignment to adjuvant treatment with marrow-supported high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin or tailored therapy with Fluorouracil, epirubicin, and cyclophosphamide: Scandinavian Breast Group Study 9401.
    Brandberg Y; Michelson H; Nilsson B; Bolund C; Erikstein B; Hietanen P; Kaasa S; Nilsson J; Wiklund T; Wilking N; Bergh J;
    J Clin Oncol; 2003 Oct; 21(19):3659-64. PubMed ID: 14512398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose cyclophosphamide in combination with cisplatin or epirubicin plus rhG-CSF allows adequate collection of PBSC for autotransplantation during adjuvant therapy for high-risk cancer.
    Menichella G; Pierelli L; Scambia G; Salerno G; Benedetti Panici P; Foddai ML; Serafini R; Puglia G; Lai M; Ciarli M
    Bone Marrow Transplant; 1994 Dec; 14(6):907-12. PubMed ID: 7536071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD34+ cell dose requirements for rapid engraftment in a sequential high-dose chemotherapy regimen of paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin (CTCb) with PBPC support in metastatic breast cancer.
    Papadopoulos KP; Ayello J; Reiss RF; Troxel A; Kaufman E; Vahdat LT; Antman KH; Hesdorffer CS
    J Hematother Stem Cell Res; 1999 Aug; 8(4):357-63. PubMed ID: 10634173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxicity of the high-dose chemotherapy CTC regimen (cyclophosphamide, thiotepa, carboplatin): the Netherlands Cancer Institute experience.
    Schrama JG; Holtkamp MJ; Baars JW; Schornagel JH; Rodenhuis S
    Br J Cancer; 2003 Jun; 88(12):1831-8. PubMed ID: 12799623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant high-dose therapy with peripheral blood stem cell support for patients with high-risk breast cancer.
    Hohaus S; Martin S; Schneeweiss A; Voso MT; Schlenk RF; Wallwiener D; Bastert G; Haas R
    Cancer Chemother Pharmacol; 1999; 44 Suppl():S13-7. PubMed ID: 10602904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study.
    Ayash LJ; Elias A; Wheeler C; Reich E; Schwartz G; Mazanet R; Tepler I; Warren D; Lynch C; Gonin R
    J Clin Oncol; 1994 Jan; 12(1):37-44. PubMed ID: 7505807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tandem high-dose therapy with ifosfamide, epirubicin, carboplatin and peripheral blood stem cell support is an effective adjuvant treatment for high-risk primary breast cancer.
    Haas R; Schmid H; Hahn U; Hohaus S; Goldschmidt H; Murea S; Kaufmann M; Wannenmacher M; Wallwiener D; Bastert G; Hunstein W
    Eur J Cancer; 1997 Mar; 33(3):372-8. PubMed ID: 9155519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose chemotherapy and autologous stem cell support followed by posttransplantation doxorubicin as initial therapy for metastatic breast cancer.
    deMagalhaes-Silverman M; Bloom E; Lembersky B; Lister J; Pincus S; Rybka W; Voloshin M; Wilson J; Ball E
    Clin Cancer Res; 1997 Feb; 3(2):193-7. PubMed ID: 9815672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of adhesion molecules on CD34+ cells: CD34+ L-selectin+ cells predict a rapid platelet recovery after peripheral blood stem cell transplantation.
    Dercksen MW; Gerritsen WR; Rodenhuis S; Dirkson MK; Slaper-Cortenbach IC; Schaasberg WP; Pinedo HM; von dem Borne AE; van der Schoot CE
    Blood; 1995 Jun; 85(11):3313-9. PubMed ID: 7538823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
    Nademanee A; Sniecinski I; Schmidt GM; Dagis AC; O'Donnell MR; Snyder DS; Parker PM; Stein AS; Smith EP; Molina A
    J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.